

Fact Sheet

Juno Selection Fund – December 2024



This is a marketing communication

MANAGER COMMENTARY

This month **Melexis** decided that its shareprice had reached an attractive level and initiated the previously approved share buyback program. Management aims to spend up to € 50 million on this buyback. A clear sign that valuations are also attractive in the eyes of insiders. **Nexus** announced that approximately 80% of its shareholders have accepted the offer of € 70 per share by TA associates. We have sold all our shares. This month we strengthened our position in **Bachem**. Shortly afterwards, the company's share price suffered from a disappointing test result of Novo Nordisk's drug CagriSema. The new drug turned out to be not much better than Zepbound from competitor Eli Lilly. Since Bachem supplies both pharmaceutical companies with essential ingredients, we fail to understand the shareprice reaction. **Sartorius** announced that it has found a replacement for CEO Joachim Kreuzburg, who is leaving after 22 years. Michael Grosse will start in July 2025. Although **Soitec's** quarterly results matched its own forecasts for the first time in a long time, it appears very challenging to achieve the high expectations for the new fiscal year. The risk of renewed inventory build-up with its customers is real. We sold our remaining small position.


FUND PROFILE

Fund size	€ 270 million
Net asset value*	€ 414.42
Equity exposure	79%
# Portfolio companies	15
Weighted average market cap	€ 2.7 billion

*per participation

PERFORMANCE UP TO DECEMBER 31, 2024

Past results are no guarantee for future performance



Source: Juno Investment Partners B.V., monthly net asset value, excluding entry and exit fees; MSCI

10 YR PERFORMANCE IN FIGURES

	1 mo	YTD	1 yr	3 yrs	5 yrs	10 yrs	since inception
Juno Selection Fund	-0.1%	-10.2%	-10.2%	-23.8%	0.5%	83.0%	314.4%
MSCI Eur. Small Cap Euro (Net)	-0.3%	5.7%	5.7%	-7.7%	19.5%	96.1%	222.5%

ESG-PROFILE

SFDR-classification: Article 8

"Article 8"-products promote social and/or ecological characteristics, but do not have sustainable investing as their main objective.

For more information on Juno's sustainability policy, [click here](#). Juno Investment Partners' Principal Adverse Impact (PAI) statement can be found [here](#).

Initial investment from	€150,000.-
Add-ons from	€25,000.-
Management Fee	1.2% p/a
Performance Fee	10%
High Water Mark	Perpetual (€543.46; 31/12/21)
Entry Fee	1%
Exit Fee	0.5%
TER	1.25% (2023)
Legal Status	Mutual Fund
Fund Currency	EUR
Valuation	Monthly
Inception	January 11, 2008
Reporting	Net
Licence	AIFMD
Depository	State Street Bank
ISIN	NL0010188017
Bloomberg	JUNOSEL NA
Reuters	LP68041261



Frans Jurgens
1969



Lennart Smits
1978



Bobby Bader
1992


PORTFOLIO – TOP 5

Name	Sector
Paradox Interactive AB	Entertainment
Technogym SpA	Leisure Products
Sartorius AG	Life Sciences Tools & Services
Cewe Stiftung & Co KGaA	Commercial Services & Supplies
Medacta Group SA	Health Care Equipment & Supplies


PORTFOLIO – CURRENCY



PORTFOLIO – SECTORS



PORTFOLIO – COUNTRIES



STRATEGY

Juno invests in highly profitable listed companies, with predictable earnings growth and preferably with management or a (founding) family as their main shareholders. Listed European family-owned companies operate with a longer term perspective and are more successful than non-family-owned companies¹⁾.

Juno aims to achieve capital growth by investing in a highly concentrated portfolio of European companies. Selection takes place based on its proprietary fundamental, bottom-up analysis including on-site visits.

A high or rising return on capital and large free cash flows are good indicators of strong companies that we are interested in. We invest with a time horizon of 3 to 5 years.

1) Source: Stiftung Familienunternehmen, A. Gregorič, M.S. Rapp, I. Requejo "Listed Family Firms in Europe, Relevance, Characteristics and Performance", 2022.

DISCLAIMER

Attention: This is a marketing communication. The information about financial markets or specific financial instruments in this document is solely intended to provide you with information about the Juno portfolio management team's view on the financial markets. This information is not an investment recommendation, nor an offer or invitation to buy or sell a financial instrument. The decision to participate in this investment fund should be taken solely on the basis of the prospectus and the key information document. You can consult these documents under 'Fund Documents' on the Fund's web page.

There are risks associated with this investment. The value of your investment may fluctuate, and past performance is no guarantee of future performance. The fund invests in stocks and stocks have a higher risk profile than bonds. The fund invests in a limited number of companies, which may lead to stronger fluctuations in the fund's net asset value than would have been the case if the fund were less concentrated. For an overview of the risks of this fund, we refer to the risk section included in the prospectus.

Juno obtains its information from sources deemed reliable, such as annual reports and other official publications, and has taken every care to ensure that the information on which it bases its view is not incorrect or misleading. The net returns presented in this communication are based on the

